Given that MEK1/2 are exquisitely specific activators of ERK1/2 and their strategic position in the MAPK/ERK (RAS-RAF-MEK-ERK) pathway, they are thus considered as potentially drug targets in cancer. This evidence concerns the gene MAPK3 and cancer.